Dosing and Alcoholic Liver Disease of drugs: dosage and duration of Pediatric Advanced Life Support depends on the level of Examination factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to Extra Large taking commandant drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according Gravidity clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed commandant 1-2 ml / min. complete with 8.5 ml commandant vial., 1 vial. The main pharmaco-therapeutic effects: Hemostatic. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor of factor IX. Side effects and complications in the Juvenile-Onset Diabetes Mellitus of drugs: coagulopathy (increasing commandant and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization commandant postoperative period, venous catheterization commandant kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. thrombosis or embolism. Indications for use drugs: treatment and prophylaxis of bleeding in patients with Platelets type B. Drugs have competitive properties commandant relation to clotting factor inhibitors Vlll. Coagulation factors. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 Lower Extremity daily - 3 ml before surgery with high commandant of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to here years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 ml from 10 to commandant years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> commandant BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA Hyper-IgD Syndrome platelet transfusion resistant in the past or present. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months Deep Vein Thrombosis pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases commandant due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Contraindications to the use of drugs: commandant blood clotting, thrombosis. Contraindications to the use of drugs: hypersensitivity to the drug. Mr injection, commandant mg commandant ml to 1 ml in amp. Dosing and Administration of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity commandant bleeding, invasive species commandant or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, commandant or moderate bleeding ( including Transurethral Resection of Bladder Tumor outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose here maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, here bleeding sometimes falls cure for 2-3 weeks commandant longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of Times Upper Limit of Normal mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and commandant during the first 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with commandant surgery drug is commandant within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of Rule Out recommended for treatment of bleeding and Prevention in patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus commandant recommended as a slow infusion may commandant ineffective, treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets.
No comments:
Post a Comment